Annexin appoints Jamal El-Mosleh as new CEO

Urban Eriksson has been appointed as the new Chairman of the board for Umeå Biotech Incubator.

Margrethe Sørgaard joins the company’s cross-functional R&D team following Calluna’s launch, to oversee the strategic development of the company’s clinical programs in line with regulatory guidelines and safety requirements. With over 25 years’ experience from different leading positions in clinical development and operation, medical affairs, and drug safety/pharmacovigilance, she will play a pivotal role in […]

Kristina Torfgård has experience in executive management, drug development, regulatory affairs and licensing with major international pharmaceutical companies, including in the field of neurodegenerative diseases. During her time at AstraZeneca, she held senior positions in both early and late-stage R&D and was globally responsible for marketed products. At the biopharmaceutical company Albireo/Pharma, she worked as […]

Margret Bessadottir has been appointed Director of Quality Operations at Coripharma and will be joining the Executive Management Team. Bessadottir has extensive experience in the pharmaceutical Industry having worked as the Quality Manager of Florealis and prior to that being a Qualified Person at Actavis. She holds a PhD in Medical Life Science from the […]

The SciLifeLab board has appointed Professor Jan Ellenberg as the new Director. Alongside this role, Professor Ellenberg will also be appointed as a Professor at Karolinska Institutet and Affiliated Professor at Stockholm University and KTH Royal Institute of Technology. He succeeds Professor Olli Kallioniemi, who has served as SciLifeLab Director since 2015. Ellenberg is moving […]

Maria Alfaiate will join Lundbeck on 1 August 2024 and will be part of the Executive Management team. Maria Alfaiate will be responsible for strengthening corporate strategic functions and enhancing global marketing efforts. Her focus will be on optimizing Lundbeck’s ability to capitalize on both present and future opportunities. She brings significant experience from the […]

Robert Edfors is appointed as new Chief Scientific Officer and Senior Vice President Clinical Development. Robert Edfors, MD, PhD will assume the new role on September 1, 2024. Up until then, Thomas Olin will remain as CSO. Thomas Olin, PhD, one of Kancera’s co-founders, possesses extensive expertise concerning the fractalkine program and will continue to […]